Metronomic oral combination chemotherapy with capecitabine and cyclophosphamide: a phase II study in patients with HER2-negative metastatic breast cancer
Cancer Chemotherapy and Pharmacology,  Clinical Article

Yoshimoto M et al. – Oral XC is an effective first– or second–line therapy for metastatic breast cancer (MBC), demonstrating high activity in both luminal A and triple–negative disease with few severe side effects. This metronomic oral combination chemotherapy could be beneficial for the treatment of HER2–negative MBC.

Methods
  • Patients received capecitabine 828mg/m2 twice daily with cyclophosphamide 33mg/m2 twice daily, days 1–14 every 3weeks.
  • The primary endpoint was overall response rate (ORR).
  • Secondary endpoints included progression-free survival (PFS), overall survival (OS), and safety.

Results
  • Between May 2007 and April 2009, 51 patients were enrolled and 45 were included in the efficacy analysis.
  • The median follow-up was 18.1months.
  • ORR was 44.4% and stable disease (≥24weeks) was achieved in 13.4%, resulting in a 57.8% clinical benefit response rate.
  • Median PFS was 12.3months (95% confidence interval: 8.9-18.9months).
  • Median PFS was 10.7months in triple-negative disease and 13.2months in estrogen-receptor positive, HER2-negative disease.
  • The 1- and 2-year OS rates were 86 and 71%, respectively.
  • Median OS has not been reached.
  • Grade 3 adverse events comprised leukopenia (26%), neutropenia (16%), and decreased hemoglobin (2%).
  • There was no grade 3 hand-foot syndrome.

Please login or register to follow this author.
Are you sure you want to Unfollow this Author?
► Click here to access PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

Your Unread Messages in Oncology

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Oncology Articles

Indexed Journals in Oncology: Journal of Clinical Oncology, Cancer Research, Annals Oncologymore

Register now to view all the MDLinx contents (FREE)!

  • Stay current on the latest literature, research and clinical news
  • Get special communications and offers from MDLinx and our sponsors
  • Receive invitations to paid market research
View Samples and Register

Connect with us, stay current.

Receive the latest mecial news
updates for free via email

Sign up!

Subscribe to our free RSS feeds:

Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More

Close